Search research articles
Contact Us
Filters
Showing results (1111-1120 of 1,460) with videos related to
Page
of 146
Sort By:
Clinical Genitourinary Cancer
|
January 10, 2025
Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
Stephanie Lakritz, Andrew Nicklawsky, Vida Alami, et al.
MMWR. Morbidity and Mortality Weekly Report
|
February 2, 2018
Acute Illnesses and Injuries Related to Total Release Foggers - 10 States, 2007-2015
Ruiling Liu, Walter A Alarcon, Geoffrey M Calvert, et al.
Alimentary Pharmacology & Therapeutics
|
April 1, 2026
Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia
Paul Y Kwo, Laura E Telep, Lai San Hong, et al.
Plos One
|
April 12, 2013
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
Barney S Graham, Mary E Enama, Martha C Nason, et al.
Plos One
|
February 4, 2010
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
Richard A Koup, Mario Roederer, Laurie Lamoreaux, et al.
The Journal of Infectious Diseases
|
May 2, 2013
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
Julie E Ledgerwood, Kathryn Zephir, Zonghui Hu, et al.
Journal of Immunology Research
|
March 26, 2019
Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar
Reham A Al Kahlout, Gheyath K Nasrallah, Elmoubasher A Farag, et al.
Vaccine
|
February 13, 2025
Evaluation of a nanoparticle influenza vaccine in the pig model
Pauline M van Diemen, Fabian Z X Lean, Andrew Ramsay, et al.
AIDS Research and Human Retroviruses
|
May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group
M C Keefer, B S Graham, M J McElrath, et al.
Cancers
|
September 14, 2024
Targeting Asparagine Metabolism in Well-Differentiated/Dedifferentiated Liposarcoma
Kyle D Klingbeil, Blake R Wilde, Danielle S Graham, et al.
Page
of 146
Search research articles
Search
Showing results (1111-1120 of 1,460) with videos related to
Sort By:
Page
of 146
Clinical Genitourinary Cancer
|
January 10, 2025
Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
Stephanie Lakritz, Andrew Nicklawsky, Vida Alami, et al.
MMWR. Morbidity and Mortality Weekly Report
|
February 2, 2018
Acute Illnesses and Injuries Related to Total Release Foggers - 10 States, 2007-2015
Ruiling Liu, Walter A Alarcon, Geoffrey M Calvert, et al.
Alimentary Pharmacology & Therapeutics
|
April 1, 2026
Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia
Paul Y Kwo, Laura E Telep, Lai San Hong, et al.
Plos One
|
April 12, 2013
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
Barney S Graham, Mary E Enama, Martha C Nason, et al.
Plos One
|
February 4, 2010
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
Richard A Koup, Mario Roederer, Laurie Lamoreaux, et al.
The Journal of Infectious Diseases
|
May 2, 2013
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
Julie E Ledgerwood, Kathryn Zephir, Zonghui Hu, et al.
Journal of Immunology Research
|
March 26, 2019
Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar
Reham A Al Kahlout, Gheyath K Nasrallah, Elmoubasher A Farag, et al.
Vaccine
|
February 13, 2025
Evaluation of a nanoparticle influenza vaccine in the pig model
Pauline M van Diemen, Fabian Z X Lean, Andrew Ramsay, et al.
AIDS Research and Human Retroviruses
|
May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group
M C Keefer, B S Graham, M J McElrath, et al.
Cancers
|
September 14, 2024
Targeting Asparagine Metabolism in Well-Differentiated/Dedifferentiated Liposarcoma
Kyle D Klingbeil, Blake R Wilde, Danielle S Graham, et al.
Page
of 146